| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,380,000 |
| Market
Cap: |
35.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $1.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health, including woman-controlled contraception and protection from certain sexually transmitted infections. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, prescription contraceptive gel for women. Co. is evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. The FDA has designated Phexxi, using the investigational name EVO100, as a Qualified Infectious Disease Product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
114 |
114 |
114 |
| Total Sell Value |
$0 |
$10 |
$10 |
$10 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nohra Guy P |
Former 10% Owner |
– – – |
2015-12-30 |
4 |
S |
$1.44 |
$360,000 |
D/D |
(250,000) |
1,339,776 |
|
- |
|
| Nohra Guy P |
Former 10% Owner |
– – – |
2015-12-29 |
4 |
S |
$1.53 |
$755,291 |
D/D |
(493,654) |
1,589,776 |
|
- |
|
| Nohra Guy P |
Former 10% Owner |
– – – |
2015-12-28 |
4 |
S |
$1.59 |
$86,389 |
D/D |
(54,333) |
2,083,430 |
|
- |
|
| Locke Kenneth W |
Chief Scientific Officer |
• – – |
2015-12-17 |
4 |
S |
$1.26 |
$753 |
D/D |
(598) |
0 |
|
- |
|
| Knudson Susan A. |
Chief Financial Officer |
• – – |
2015-12-17 |
4 |
S |
$1.26 |
$1,266 |
D/D |
(1,005) |
0 |
|
- |
|
| Nohra Guy P |
10% Owner |
– – • |
2015-12-15 |
4 |
S |
$1.44 |
$762,136 |
D/D |
(529,261) |
2,137,763 |
|
- |
|
| Locke Kenneth W |
Chief Scientific Officer |
• – – |
2015-11-18 |
4 |
AS |
$8.30 |
$50,619 |
D/D |
(6,098) |
293 |
|
- |
|
| Locke Kenneth W |
Chief Scientific Officer |
• – – |
2015-11-18 |
4 |
OE |
$8.30 |
$50,619 |
D/D |
6,098 |
6,391 |
|
- |
|
| Mahaffey George W |
President and CEO |
• • – |
2015-10-15 |
4 |
D |
$8.60 |
$229,457 |
D/D |
(26,681) |
171,040 |
|
- |
|
| Kemmerer Christopher |
VP, Pharma Dev & Manufacturing |
• – – |
2015-09-18 |
4 |
AS |
$12.20 |
$12,195 |
D/D |
(1,000) |
10,848 |
|
- |
|
| Kemmerer Christopher |
VP, Pharma Dev & Manufacturing |
• – – |
2015-09-18 |
4 |
OE |
$1.34 |
$1,342 |
D/D |
1,000 |
11,848 |
|
- |
|
| Knudson Susan A. |
Chief Financial Officer |
• – – |
2015-09-01 |
4 |
AS |
$11.33 |
$33,990 |
D/D |
(3,000) |
492 |
|
- |
|
| Knudson Susan A. |
Chief Financial Officer |
• – – |
2015-09-01 |
4 |
OE |
$1.22 |
$3,660 |
D/D |
3,000 |
3,492 |
|
- |
|
| Kemmerer Christopher |
VP, Pharma Dev & Manufacturing |
• – – |
2015-08-07 |
4 |
AS |
$12.88 |
$12,880 |
D/D |
(1,000) |
10,848 |
|
- |
|
| Kemmerer Christopher |
VP, Pharma Dev & Manufacturing |
• – – |
2015-08-07 |
4 |
OE |
$1.22 |
$1,220 |
D/D |
1,000 |
11,848 |
|
- |
|
| Kemmerer Christopher |
VP, Pharma Dev & Manufacturing |
• – – |
2015-06-12 |
4 |
OE |
$1.22 |
$13,235 |
D/D |
10,848 |
10,848 |
|
- |
|
| Mahaffey George W |
President and CEO |
• • – |
2015-03-19 |
4 |
B |
$7.76 |
$7,757 |
D/D |
1,000 |
197,721 |
2.81 |
- |
|
| Shah Nimesh |
10% Owner |
– – • |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,934 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
B |
$14.00 |
$980,000 |
D/D |
70,000 |
3,091,643 |
2.45 |
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
D |
$14.00 |
$2,202,438 |
D/D |
(157,317) |
3,021,643 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
OE |
$8.54 |
$2,202,423 |
D/D |
257,895 |
3,122,775 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,921,065 |
2,921,065 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
D |
$14.00 |
$37,562 |
D/D |
(2,683) |
48,025 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
OE |
$8.54 |
$37,550 |
D/D |
4,397 |
49,750 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2014-11-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
46,311 |
46,311 |
|
- |
|
194 Records found
|
|
Page 7 of 8 |
|
|
